Selected stock price target news of the day - March 17th, 2025

By: Matthew Otto

Veritone Reports Q4 EPS Beat, Provides FY2025 Revenue Outlook Below Consensus

Veritone reported its financial results posting Q4 EPS of $0.72, surpassing the analyst estimate of ($0.26) by $0.98. Revenue for the quarter totaled $22.4 million, exceeding the consensus estimate of $19.86 million.

For the full year, Veritone recorded revenue of $92.6 million, aligning with prior guidance. Software and Managed Services revenue for Q4 came in at $15.5 million and $6.9 million, respectively. Veritone reported an Annual Recurring Revenue (ARR) of $58.8 million, with 81% of this derived from subscription-based customers. Despite a 7% year-over-year decline in total revenue, Veritone improved its loss from operations to $86.8 million, a 13% reduction compared to 2023. Net loss narrowed to $37.4 million from $58.6 million in the prior year, while non-GAAP gross margin declined slightly to 71.6%.

Looking ahead, Veritone provided guidance for Q1 2025 revenue of $23 to 24 million, below the consensus estimate of $27.106 million. For full-year 2025, Veritone expects revenue between $107 To 122 million, compared to the consensus of $110.7 million.

Analysts Provide Mixed Ratings and Varied Price Targets

Ladenburg Thalmann initiated a Buy rating and a $6 price target.
D. Boral Capital analyst Jesse Sobelson maintained a Buy rating and the $4.50 price target.
HC Wainwright & Co. analyst Scott Buck reiterated a Buy rating and a $6 price target.

Which Analyst has the best track record to show on VERI?

Analyst Karl Keirstead (UBS) currently has the highest performing score on VERI with 4/5 (80%) price target fulfillment ratio. His price targets carry an average of $0.32 (19.05%) potential upside. Veritone stock price reaches these price targets on average within 125 days.

Gain Therapeutics Begins Dosing in Phase 1b Trial for Parkinson’s Treatment

Gain Therapeutics has announced the dosing of the first participant in its Phase 1b clinical trial of GT-02287, an allosteric small molecule therapy for Parkinson’s disease (PD) with or without a GBA1 mutation. Parkinson’s disease affects approximately 10 million people worldwide, including 1 million in the U.S., 1.2 million in Europe, and about 4 million in Asia. An estimated 5% to 10% of PD cases—between 500,000 and 1 million people—are associated with a GBA1 mutation.

The Phase 1b trial will enroll up to 20 participants over a three-month period, assessing safety, tolerability, pharmacokinetics, GCase modulation, and biomarker changes in plasma and cerebrospinal fluid. Interim results are expected by the end of Q2 2025. This follows the Phase 1 study completed in Q3 2024, in which GT-02287 demonstrated a >50% increase in glucocerebrosidase (GCase) activity, along with favorable safety and CNS exposure.

Parkinson’s disease is the second most common neurodegenerative disorder, with cases projected to rise to 17 million by 2040 due to aging populations. Approximately 90% of those diagnosed experience progressive neurodegeneration, and around 60% develop cognitive impairment over time.

The total economic burden of Parkinson’s disease in the U.S. was estimated at $52 billion in 2019, with direct medical costs accounting for $25.4 billion. The global market for Parkinson’s treatments was valued at approximately $5 billion in 2023, with disease-modifying therapies under investigation.

Analyst Reaffirms Rating and Price Target Amid Clinical Progress

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating and a $8 price target.

Which Analyst has the best track record to show on GANX?

Analyst Mayank Mamtani (B. RILEY) currently has the highest performing score on GANX with 1/4 (25%) price target fulfillment ratio. His price targets carry an average of $1.34 (36.61%) potential upside. Gain Therapeutics stock price reaches these price targets on average within 214 days.

Docusign Posts Q4 Revenue Beat and EPS Surprise, Issues FY2026 Guidance Below Consensus

Docusign announced its financial results with fourth-quarter total revenue reaching $776.3 million, exceeding the consensus estimate of $760.99 million. This reflects a 9% year-over-year increase. Subscription revenue rose to $757.8 million, while professional services and other revenue totaled $18.5 million, an 11% increase. Billings for the quarter grew 11% to $923.2 million.

Gross margin was 79.4%, compared to 79.2% in the same period last year. Earnings per diluted share came in at $0.86, beating analyst expectations of $0.84 and rising from $0.76 a year ago. Free cash flow increased to $279.6 million compared to $248.6 million in the prior-year quarter, and Docusign ended the quarter with $1.1 billion in cash, cash equivalents, restricted cash, and investments.

For the full fiscal year 2025, total revenue grew 8% to $2.98 billion, with subscription revenue increasing to $2.90 billion and professional services revenue remaining stable at $75.4 million. Billings rose 7% to $3.1 billion. Earnings per diluted share improved to $5.08 from $0.36 in fiscal 2024, while adjusted earnings per diluted share increased to $3.55 from $2.98. Docusign repurchased $683.5 million in common stock, up from $145.5 million the previous year.

Looking ahead, Docusign provided guidance for fiscal 2026, forecasting total revenue between $3.129 billion and $3.141 billion, below the consensus estimate of $3.15 billion. For the first quarter of fiscal 2026, Docusign expects revenue in the range of $745 million to $749 million, falling short of the consensus estimate of $755.7 million. Docusign also anticipates a gross margin of 80.5% to 81.5% and an operating margin of 27.8% to 28.8% for the full fiscal year.

Analyst Upgrades to Outperform on Growth Potential

William Blair analyst Bhavan Suri upgraded from Market Perform to Outperform.

Which Analyst has the best track record to show on DOCU?

Analyst Mark Murphy (JPMORGAN) currently has the highest performing score on DOCU with 4/7 (57.14%) price target fulfillment ratio. His price targets carry an average of $-4.76 (-5.55%) potential downside. Docusign stock price reaches these price targets on average within 22 days.